stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) Current ratio
Penumbra, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 5.9×, down 0.8× from fiscal 2025 (6.6×). Over the past ten years it has ranged from 5.1× (fiscal 2019) to 8.7× (fiscal 2015); the current reading is higher than 73% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 6.6× | 10.60% |
| FY2024 | 6.0× | (0.82%) |
| FY2023 | 6.1× | 16.15% |
| FY2022 | 5.2× | (5.74%) |
| FY2021 | 5.5× | (5.14%) |
| FY2020 | 5.8× | 14.63% |
| FY2019 | 5.1× | (18.18%) |
| FY2018 | 6.2× | (16.10%) |
| FY2017 | 7.4× | 0.55% |
| FY2016 | 7.4× | (15.11%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 5.9× | 2.40% |
| Jun 2026 | 5.7× | (4.55%) |
| Mar 2026 | 6.0× | (9.33%) |
| Dec 2025 | 6.6× | (1.29%) |
| 41 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PEN Penumbra, Inc. | 5.9× |
| TXG 10x Genomics compare | 5.7× |
| GKOS Glaukos Corporation compare | 4.6× |
| GMED Globus Medical, Inc. compare | 4.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.2× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.2× |
| PODD Insulet Corporation compare | 2.5× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.1× |
| BRKR Bruker Corporation compare | 1.8× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on PEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement